Last reviewed · How we verify

ABT-335 plus rosuvastatin — Competitive Intelligence Brief

ABT-335 plus rosuvastatin (ABT-335 plus rosuvastatin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrate + statin combination. Area: Cardiovascular.

phase 3 Fibrate + statin combination PPARα (ABT-335); HMG-CoA reductase (rosuvastatin) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

ABT-335 plus rosuvastatin (ABT-335 plus rosuvastatin) — AstraZeneca. ABT-335 (fenofibrate analog) combined with rosuvastatin reduces triglycerides and LDL cholesterol through dual lipid-lowering pathways.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ABT-335 plus rosuvastatin TARGET ABT-335 plus rosuvastatin AstraZeneca phase 3 Fibrate + statin combination PPARα (ABT-335); HMG-CoA reductase (rosuvastatin)
ABT-335 and simvastatin ABT-335 and simvastatin Abbott phase 3 Fibrate + statin combination PPARα (ABT-335); HMG-CoA reductase (simvastatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrate + statin combination class)

  1. Abbott · 1 drug in this class
  2. AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABT-335 plus rosuvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/abt-335-plus-rosuvastatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: